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Successful commercialisation of cell therapies will be underpinned by cost-effective, robust and
scalable manufacturing processes, practical supply chain solutions for delivery to patients and early
planning of reimbursement. UCL’s Decisional Tools team have developed advanced decision-support
tools that effectively integrate concepts from bioprocess economics, risk analysis, and combinatorial
optimization to address such challenges. This presentation will provide some of our most recent process
economic insights from such models applied to current and future cell therapy manufacturing processes.
Bottlenecks in upstream and downstream processes will be identified and the technical innovation
required to bridge the gaps constraining commercialisation will be discussed. Parallels and key
differences with the historical development of biopharmaceuticals will be highlighted. A discussion of
the cost of goods in relation to reimbursement will be provided for different cell therapies and compared
to biopharmaceuticals. A series of industrial case studies will be presented to highlight economic
challenges for different allogeneic and autologous cell therapy products. The case studies will address
questions such as: What are the most cost-effective process technologies to use for cell culture,
differentiation and recovery for different allogeneic and autologous scenarios? What are the cost and
risk implications of process changes to more scalable and cost-effective technologies at different stages
of a cell therapy’s lifecycle? How do the lower costs of commercial manufacture with microcarrier
systems relative to planar technologies weigh up against the cost of development? What is the impact
of centralised versus decentralised facility designs on the costs of manufacturing and logistics to reach
the patients. The insights from such questions are critical to helping the cell therapy sector achieve the
manufacturing and commercial success of biopharmaceuticals.

